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Abstract. Triple-negative breast cancer (TNBC) has a 
poorer prognosis compared with other sub-groups. In the 
current study, survival associated with locoregional treat-
ment of females with TNBC was investigated. Specifically, 
468 patients with stage I-III TNBC treated between 2002 
and 2009 were identified. Data included patient and tumor 
characteristics, treatment received and survival. Data 
were compared using χ2 and Fisher's exact tests, as well 
as MANOVA. Kaplan-Meier curves were generated. The 
study cohort had a mean age of 54±13 years old with a 
mean follow-up period of 51±21 months. Of 468 patients, 
249 (53%) underwent lumpectomy, 63 (14%) underwent 
simple mastectomy (SM) and 156 (33%) underwent modified 
radical mastectomy (MRM). Overall, 263 (56%) received 
adjuvant radiation, including 178/249 (71%) following 
lumpectomy, 13/63 (21%) following SM and 72/156 (46%) 
following MRM (P<0.0001). Following control for poten-
tial confounders in univariate tests, adjuvant radiation was 
associated with improved overall survival in the total cohort 
(HR, 0.46; 95% CI, 0.31-0.68; P=0.0001). When comparing 
survival by surgical type, receipt of adjuvant radiation signif-
icantly improved survival in the lumpectomy group (HR, 
0.30; 95% CI, 0.16-0.58; P=0.0004), but was not associated 
with improved survival in the SM group (HR, 0.38; 95% CI, 
0.05-3.04; P=0.36) or in the MRM group (HR, 0.79; 95% CI, 
0.46‑1.34; P=0.38). The survival benefit of adjuvant radia-
tion in these TNBC patients is attributed to those undergoing 
breast‑conserving therapy. There was no benefit in either 
mastectomy group. These data warrant validation from 
prospective trials, in order to develop tailored locoregional 
treatment for patients with TNBC.
Introduction
Triple-negative breast cancer (TNBC) accounts for 15-20% of 
all breast cancers in the USA (1-3). Treatment for TNBC [tumors 
that are estrogen receptor (ER)-negative, progesterone receptor 
(PR)-negative and human epidermal growth factor receptor 2 
(HER2) non‑amplified] continues to be a challenge due to the 
fact that it is, by definition, insensitive to the hormonal therapies 
and trastuzumab that have been developed to treat other types 
of breast cancer. These tumors appear to be exquisitely sensitive 
to chemotherapy with reported complete pathological response 
in 21-31% of TNBC tumors in patients treated with neoadjuvant 
chemotherapy (4,5). Despite this, these tumors are considered 
aggressive and have shorter intervals for locoregional recur-
rence, distant metastasis and disease-free survival (1,6-8). 
Gene expression profiling has resulted in the classification 
of breast cancer into five molecular subtypes: Luminal A 
(ER+, PR+ and Her2-), luminal B (ER+, PR+ and Her2+), 
basal-like (ER-, PR- and Her2-; triple-negative) Her2-enriched 
(ER-/PR-/Her2+) and the normal breast-like subtype. Recent 
studies have focused on whether molecular subtype is indica-
tive of prognosis and response to treatment, but the data on 
directed-associated treatment is still in its infancy (6-8). As a 
result, chemotherapy continues to be the mainstay of treatment 
for TNBC breast cancers. However, recently, there has been 
interest in determining whether radiation therapy provides any 
additional benefit to patients with TNBC tumors, regardless of 
initial surgical management.
There are currently no specialized guidelines for the treat-
ment of TNBC. In general, radiation therapy is indicated for 
all patients with invasive carcinoma of the breast under the 
following conditions: i) received breast-conserving therapy 
(BCT); ii) underwent mastectomy with tumor >5 cm or with 
positive margins; or iii) underwent mastectomy with positive 
axillary nodes. Recently, however, there have been several 
studies that have aimed to determine the outcomes of patients 
with TNBC tumors who received radiation therapy, in compar-
ison to those who did not. The results of these studies appear to 
indicate that patients with TNBC tumors who received radia-
tion therapy had decreased risk of locoregional recurrence and 
increased overall survival in comparison to those that did not 
receive radiation therapy (9,10). As a result, the present study 
was performed in order to determine whether similar results 
were observed in our study population.
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Μaterials and methods
Study design. Approval from the institutional review board 
of Washington University School of Medicine (St. Louis, 
MO, USA) was obtained prior to the initiation of this study. 
It was determined that written consent from patients was 
not required given the retrospective nature of the study. We 
retrospectively identified 493 patients from our prospectively 
maintained database with a diagnosis of stage I-III TNBC 
who were treated between January 1, 2002 and December 
31, 2009. Of these, 25 patients were diagnosed with stage IV 
breast cancer at the time of diagnosis and subsequently 
excluded from the analysis. As a result, 468 patients were 
included in the total study population. Patients were deter-
mined to have a TNBC based on immunohistochemical 
methods. A designation of receptor negative status was 
conducted based on having <1% stained cells. Fluorescence 
in situ hybridization was used to confirm HER‑2/neu status 
if immunohistochemistry detected 2+ staining. Patients 
were subsequently divided based on whether they under-
went lumpectomy or BCT versus simple mastectomy (SM) 
versus modified radical mastectomy (MRM). Data collected 
included patient and tumor characteristics; surgical, systemic 
and radiation treatment received; and breast cancer‑specific 
survival.
Statistical analysis. The primary outcome was overall survival 
(OS), which was defined as time from the date of treatment 
initiation to the date of mortality due to any cause. Survivors 
were censored at the date of last contact. The distributions of 
patient and clinical characteristics (including age, ethnicity, 
nodal status, tumor grade and size, receipt of chemotherapy and 
type of surgery) by the status of radiotherapy were compared 
using χ2 or Fisher's exact tests, as appropriate. Survival curves 
by radiotherapy status were estimated using the Kaplan-Meier 
product-limit method and compared by the log-rank test. 
Univariate Cox proportional hazard models were fit to identify 
factors significantly associated with OS. For those factors with 
P<0.15 in the univariate analyses, a multivariate Cox model 
was constructed using a backward selection procedure to 
assess whether the receipt of radiotherapy was an independent 
predictor of survival. Two-way interaction terms between 
radiotherapy and other factors in the multivariate Cox model 
were also assessed. All analyses were two-sided and P<0.05 
was considered to indicate a statistically significant difference. 
Statistical analyses were performed using SAS (SAS Institute, 
Cary, NC, USA).
Results
During the study period, between January 2002 and 
December 2009, 468 patients with stage I‑III TNBC were 
identified. Of 468 patients, 249 (53%) underwent lumpectomy, 
63 (14%) underwent simple mastectomy and 156 (33%) under-
went modified radical mastectomy. The mean age of the study 
population was 54±13 years old with a mean follow-up period 
of 51±21 months. The patient and tumor characteristics of the 
study population are described in Table Ι.
Overall, 263 (56%) received adjuvant radiation therapy, 
including 178/249 (71%) following lumpectomy, 13/63 (21%) 
following SM and 72/156 (46%) following MRM (P<0.0001), 
as listed in Table ΙΙ. Of the 263 patients that received adju-
vant radiation therapy, information regarding their treatment 
regimen was only available for 152 patients (57.8%). For these 
patients, the mean initial radiation dose was 5,137±938 cGy 
with a range of 2,000-10,240 cGy and median of 5,000 cGy. 
Of these patients, 84 (55.3%) went on to receive an additional 
boost of radiation with a mean of 1,292±629 cGy, median of 
1,000 cGy and range of 1,000-6,400 cGy. Factors predictive of 
receipt of adjuvant radiation included type of surgical therapy 
received (lumpectomy vs. SM and MRM), increasing tumor 
size and positive nodal status (P<0.05 for each). The groups 
did not differ with regard to age, ethnicity, tumor size or 
nuclear grade (Table III).
Table I. Patient and tumor characteristics of 468 patients with 
triple-negative breast cancer treated between 2002 and 2009.
Characteristic n (%)
Age, years
  <50 193 (41.2)
  ≥50 275 (58.8)
Ethnicity
  Caucasian 287 (61.3)
  African American 172 (36.8)
  Other     9 (1.9)
Clinical T stage
  T1 166 (35.5)
  T2 176 (37.6)
  T3   37 (7.9)
  T4   30 (6.4)
  Unknown   59 (12.6)
Histology
  Invasive ductal 386 (82.5)
  Invasive lobular     9 (1.9)
  Mixed/other   73 (15.6)
Nuclear grade
  1     6 (1.3)
  2   55 (11.8)
  3 391 (83.6)
  Unknown   16 (3.4)
Node status
  N0 295 (63.0)
  N1 100 (21.4)
  N2   12 (2.6)
  N3   16 (3.4)
  Unknown   45 (9.6)
Stage
  1 149 (31.8)
  2a 142 (30.3)
  2b   54 (11.5)
  3   66 (14.1)
  Unknown   57 (12.2)
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In the total cohort, univariate analysis demonstrated 
that TNBC patients who underwent radiation therapy had 
significantly improved overall survival (HR, 0.462; 95% CI, 
0.311-0.69; P=0.0001) compared with those who did not 
receive adjuvant radiation therapy. The overall four-year 
survival for patients who received adjuvant radiation therapy 
was 77.34 versus 59.8% in patients who did not receive adju-
vant radiation therapy. Smaller tumor size (T1/T2), negative 
nodal status, receipt of systemic chemotherapy and receipt of 
adjuvant radiation therapy were all significantly associated 
with improved overall survival (P<0.05 for each). However, 
when comparing survival by surgical type, receipt of adju-
vant radiation therapy significantly improved survival in the 
lumpectomy group (HR, 0.30; 95% CI, 0.16-0.58; P=0.001), 
but was not significantly associated with improved survival 
in the SM group (HR, 0.38; 95% CI, 0.05-3.04; P=0.34) or in 
the MRM group (HR, 0.77; 95% CI, 0.46-1.34; P=0.38). Fig. 1 
illustrates the survival curves for all TNBC study patients, 
as well as the survival curves for patients treated by surgical 
intervention. Overall four-year survival for patients treated by 
surgical intervention was 78.9, 81.78 and 54.26% for lumpec-
tomy, SM and MRM groups, respectively.
Discussion
The majority of studies have shown that TNBC is a particu-
larly aggressive form of breast cancer. These tumors tend 
to present in younger patients, at a larger size (>2 cm), 
Table II. Locoregional treatment of 468 patients with triple-negative breast cancer.
Type of surgery Received radiation, n (%) No radiation, n (%)
Breast-conserving therapy 178 (71.5) 71 (28.5)
Simple mastectomy   13 (20.6) 50 (79.4)
Modified radical mastectomy   72 (46.2) 84 (53.8)
Figure 1. Kaplan-Meier survival curves for 468 patients with triple-negative breast cancer according to receipt of adjuvant radiation therapy versus no radiation 
therapy (RT). (A) Entire cohort of 468 patients. (B) Patients who underwent lumpectomy (n=249). (C) Patients who underwent simple mastectomy (n=63). 
(D) Patients who underwent modified radical mastectomy (MRM) (n=156).
  A   B
  C   D
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with positive lymph nodes and with a higher mitotic index 
and grade (3,8). Patients with TNBC demonstrate poorer 
overall breast cancer‑specific survival and shorter time to 
recurrence, including locoregional recurrence and distant 
metastasis (3,8,11,12). In addition, studies have also docu-
mented that the incidence of locoregional recurrence in 
TNBC patients peaks during years 1-4, but then sharply 
declines (8). Another study demonstrated that individuals 
with TNBC were more likely to have locoregional failure, 
in comparison to distant metastasis (11). As a result, the 
impetus for identifying the optimal locoregional treatment 
strategy for TNBC is of paramount importance. Yet, the 
connection between locoregional control and survival has yet 
to be elucidated for this sub-group of patients.
Currently, there are no specific guidelines for the manage-
ment of TNBC. Systemic chemotherapy continues to be the 
mainstay of treatment, as the majority of TNBCs tend to be 
exquisitely sensitive to chemotherapy. However, how this 
systemic therapy specifically impacts locoregional control 
remains less clear. Radiation therapy is indicated for the 
majority of patients who undergo BCT and is also indicated 
for a sub-set of patients following mastectomy if high-risk 
features for locoregional recurrence exist, for example 
multiple positive lymph nodes, tumors >5 cm, presence of 
lymphovascular invasion or positive surgical margins. There 
are no tumor subtype‑specific guidelines regarding adjuvant 
radiation therapy. Given that adjuvant radiation therapy is used 
for local control and TNBCs appear to have a higher incidence 
of locoregional recurrence, there has been recent interest in 
determining whether TNBC, a specific subtype of breast 
cancer, is likely to benefit from radiation therapy regardless of 
surgical intervention. Therefore, several retrospective studies 
have analyzed the role of radiation therapy in TNBC, but their 
findings are conflicting (11‑14).
Dragun et al found that there was no difference in progres-
sion-free and locoregional-free survival in TNBC patients with 
or without radiation therapy during years 1-3. However, the 
radiation group had a higher probability of locoregional-free 
survival after three years (13). Abdulkarim et al found that 
T1-2N0 TNBC patients treated with MRM without RT had 
a significantly increased risk of locoregional recurrence in 
comparison with those treated with BCT, but there was no 
Table III. Correlation between patient and tumor characteristics and receipt of radiation therapy in 468 patients with triple-neg-
ative breast cancer.
Characteristic Radiation, n (%) No radiation, n (%) P-value
Age, years
  <50 83 (40.5) 110 (41.8) NS
  ≥50 122 (59.5) 153 (58.2)
Ethnicity
  Caucasian 125 (61.0) 162 (61.6) NS
  African American 77 (37.6) 95 (36.1)
  Other 3 (1.5) 6 (2.3)
Clinical T stage
  T1 72 (35.1) 94 (35.7) NS
  T2 75 (36.6) 101 (38.4)
  T3 14 (6.8) 23 (8.8)
  T4 11 (5.4) 19 (7.2)
  Unknown 33 (16.1) 26 (9.9)
Nuclear grade
  1 2 (1.0) 4 (1.5) NS
  2 22 (10.7) 33 (12.6)
  3 170 (82.9) 291 (84.0)
  Unknown 11 (5.4) 5 (1.9)
Node status
  N0 141 (68.8) 154 (58.6) 0.0047
  N1 37 (18.1) 63 (24.0)
  N2 0 (0) 12 (4.6)
  N3 7 (3.4) 9 (3.4)
  Unknown 20 (9.8) 25 (9.5)
Chemotherapy
  Adjuvant 106 (51.7) 128 (48.7) <0.0001
  Neoadjuvant 45 (22.0) 106 (40.3)
  Unknown 54 (26.3) 22 (11.0)
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difference in overall survival (9). Wang et al completed a 
randomized trial comparing adjuvant chemotherapy versus 
adjuvant chemotherapy and radiation in stage I and II TNBCs 
who underwent modified radical mastectomy. The authors 
found improved recurrence-free and overall survival in patients 
who received combined therapy in comparison to those who 
only received chemotherapy (10). While the data appears to 
be inconsistent with respect to whether radiation decreases 
locoregional recurrence, there is even less clear evidence of 
the effect of radiation therapy on survival.
The current study has several limitations. Firstly, this 
is a retrospective study and, therefore, patients were not 
randomized to receipt of radiation therapy. There are specific 
guidelines regarding indications for adjuvant radiation 
therapy, but it is clear that adherence to these guidelines 
may not always occur and the reasons for this are unclear 
retrospectively. For example, it is noteworthy that of the 
249 patients who underwent BCT, 71 patients (28.5%) did not 
receive any radiation therapy. It would be interesting to know 
if there were clinicopathological versus social factors that 
affected why these patients did not receive radiation. Another 
weakness of the study is the lack of consistency amongst the 
treatment regimens, including the radiation therapy regimen 
and whether or not patients received chemotherapy. The 
median radiation dose was 5,000 cGy and ~50% of those 
patients received an additional median boost of 1,000 cGy. 
These are fairly standard regimens, but the regimens did 
vary, reflecting the heterogeneity of patients that receive 
some or all of their care at our single institution. In future 
prospective studies, a more standardized radiation therapy 
must be outlined.
Although the retrospective nature of this study is a 
potential limitation, we propose that it represents one of the 
largest analyses of the impact of adjuvant radiation therapy 
in patients with TNBC, with the primary goal of determining 
the impact of radiation therapy on overall survival, rather than 
on locoregional recurrence. The study indicates that, while 
overall survival of patients with TNBC improved with radia-
tion therapy, this improvement was attributed to those patients 
who underwent BCT. There was no difference in the overall 
survival of patients who underwent either form of mastectomy 
according to receipt of radiation therapy. These observations 
corroborate those documented by Kyndi et al in their study 
of high-risk patients who underwent MRM (14). The authors 
also found no survival benefit for post‑mastectomy radiation in 
patients with TNBC.
Radiation therapy is not innocuous, nor is it without cost. 
Determining whether certain sub‑groups of patients with 
TNBC may be able to forego adjuvant radiation therapy is of 
significant clinical interest.
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